CM Hospitalar SA
BOVESPA:VVEO3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
CM Hospitalar SA
BOVESPA:VVEO3
|
BR |
|
Dream Finders Homes Inc
NYSE:DFH
|
US |
|
Movado Group Inc
NYSE:MOV
|
US |
|
T
|
Tanger Inc
SWB:T6O
|
US |
|
freee KK
TSE:4478
|
JP |
|
Grupo Nutresa SA
OTC:GCHOY
|
CO |
|
Sajodongaone Co Ltd
KRX:008040
|
KR |
|
Budweiser Brewing Company APAC Ltd
HKEX:1876
|
HK |
CM Hospitalar SA
CM Hospitalar SA engages in the provision of healthcare services. The company is headquartered in Ribeirao Preto, Sao Paulo and currently employs 6,000 full-time employees. The company went IPO on 2021-08-09. The firm operates mainly in export, import, production, representation, storage, distribution, and shipment of medicines, including special control and wholesale trade in general, acting mainly in the trade in health products, as a middleman between industries and hospitals, clinics, home cares and health institutions in the private and public market, in addition to participating in other investments. The company operates throughout Brazil with a commercial and logistical structure. The firm's medium and long-term planning encompasses the acquisition of companies from the segment and an important commercial strengthening throughout Brazil, expanding its position in the distribution of medicines and hospital supplies.
CM Hospitalar SA engages in the provision of healthcare services. The company is headquartered in Ribeirao Preto, Sao Paulo and currently employs 6,000 full-time employees. The company went IPO on 2021-08-09. The firm operates mainly in export, import, production, representation, storage, distribution, and shipment of medicines, including special control and wholesale trade in general, acting mainly in the trade in health products, as a middleman between industries and hospitals, clinics, home cares and health institutions in the private and public market, in addition to participating in other investments. The company operates throughout Brazil with a commercial and logistical structure. The firm's medium and long-term planning encompasses the acquisition of companies from the segment and an important commercial strengthening throughout Brazil, expanding its position in the distribution of medicines and hospital supplies.
Performance: Revenue essentially stable vs. 2024, with fourth-quarter growth above 6% year‑over‑year and hospitals/clinics up 6.6% in Q4.
Profitability: Gross profit expanded (Q4 gross profit 15.7%, up 1.1 pp year‑over‑year) and EBITDA reached BRL 706 million with EBITDA growth of more than 19% and margin expansion quarter‑over‑quarter.
Cash generation: The company highlighted a material improvement in cash: BRL 515 million of operational cash generation in 2025 and working‑capital gains of over BRL 600 million (also referenced a BRL 20 million cash generation record earlier in the year).
Working capital & leverage: Cash cycle hit its lowest level; adjusted leverage ended below 4x (management cited 3.97x adjusted) after a Q4 covenant of 4.5x — a clear improvement across the year.
Strategy: Management completed a multi‑quarter operational overhaul: greater contract selectivity, integration of acquisitions, cost controls and simplification; new CEO Andre Clark emphasizes focus, discipline and further simplification in 2026.
Outlook & negotiations: Management expects resumed, selective growth in 2026, continued working‑capital improvement (focus on accounts receivable) and completion of debt renegotiations by mid‑2026.
